Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Taysha Gene Therapies (TSHA) Interest & Investment Income (2022 - 2025)

Historic Interest & Investment Income for Taysha Gene Therapies (TSHA) over the last 4 years, with Q3 2025 value amounting to $3.2 million.

  • Taysha Gene Therapies' Interest & Investment Income rose 5040.34% to $3.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $8.1 million, marking a year-over-year increase of 1247.03%. This contributed to the annual value of $6.9 million for FY2024, which is 9428.89% up from last year.
  • According to the latest figures from Q3 2025, Taysha Gene Therapies' Interest & Investment Income is $3.2 million, which was up 5040.34% from $1.9 million recorded in Q2 2025.
  • Over the past 5 years, Taysha Gene Therapies' Interest & Investment Income peaked at $3.2 million during Q3 2025, and registered a low of $9000.0 during Q3 2022.
  • Moreover, its 4-year median value for Interest & Investment Income was $1.3 million (2025), whereas its average is $1.1 million.
  • As far as peak fluctuations go, Taysha Gene Therapies' Interest & Investment Income skyrocketed by 1222222.22% in 2023, and later plummeted by 2167.75% in 2025.
  • Taysha Gene Therapies' Interest & Investment Income (Quarter) stood at $199000.0 in 2022, then surged by 865.33% to $1.9 million in 2023, then decreased by 11.5% to $1.7 million in 2024, then surged by 86.41% to $3.2 million in 2025.
  • Its Interest & Investment Income was $3.2 million in Q3 2025, compared to $1.9 million in Q2 2025 and $1.3 million in Q1 2025.